The Latest Breaking News on Pharma

The first case of Omicron's highly transmissible and immune-evasive descendant called BQ.1 has been detected in Thailand, according to the Centre for Medical Genomics at Ramathibodi Hospital.

Canberramine. Ketberra.

DALLAS — Although COVID-19 is presently at one of its lowest rates in the Lone Star State, one Texas-based vaccine scientist is wary of what’s to come this winter.

Experts fear the UK is in the middle of a fourth wave of Covid and with the winter fast approaching, an increase in respiratory illnesses is also on the horizon

Before Covid-19 vaccines were developed and distributed, China's strict approach to controlling the virus resulted in fewer deaths and a much lower death rate per million people than in many other countries. But while these successes were impressive in late 2020 and early 2021, effective vaccines and treatments have become…

Rats in Scotland are "learning to evade control measures", one pest expert has said.

The biotech industry is set to benefit from continued investments in breakthrough developments and federal support. Against this backdrop, fundamentally strong biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) could be solid buys. However, Relmada Therapeutics (RLMD) might be best avoided considering its weak fundamentals. Read on….

Boston University scientists combined Omicron with the original Wuhan Covid strain to make a hybrid which killed 80% of the mice it was tested on, as experts warn such research needs better accountability

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Australia's first fixed pill testing site has discovered a new recreational drug, similar to ketamine, not seen in the country before.

Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its commercialization model and is doing more licensing partnerships with multinationals to expand its drug pipeline By Molly…